Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin’s Lymphoma

DISEASE CHARACTERISTICS:

Diagnosis of non-Hodgkin's lymphoma (NHL) that has failed standard first-line chemotherapy
Measurable disease
NHL tissue Lym-1 reactive in vitro
Normocellular bone marrow as evidenced by less than 25% of the bone marrow being NHL by bilateral bone marrow biopsy
No bone marrow evidence of myelodysplastic syndrome
HAMA titer negative

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

Karnofsky 70-100%

Life expectancy:

3 to 6 months

Hematopoietic:

Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 130,000/mm^3

Hepatic:

Bilirubin no greater than 1.5 mg/dL
AST no greater than 84 U/L

Renal:

Creatinine less than 1.5 mg/dL OR
Creatinine clearance at least 50 mL/min

Cardiovascular:

LVEF at least 50%

Pulmonary:

FEV1 at least 60% of predicted
FVC at least 60% of predicted
DLCO at least 50%

Other:

No other prior malignancy within the past 5 years except for nonmelanoma skin cancer
HIV negative
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

See Disease Characteristics
At least 4 weeks since prior chemotherapy

Endocrine therapy:

Not specified

Radiotherapy:

At least 4 weeks since prior external beam radiotherapy

Surgery:

Not specified